文献速递颈动脉与弓上血管

ROADSTER关键期与扩展准入队列分析:经颈动脉支架植入联合动态血流反转1年耐久性优异

Analysis of the ROADSTER pivotal and extended-access cohorts shows excellent 1-year durability of transcarotid stenting with dynamic flow reversal.
PubMed 文献 · J Vasc Surg · 2019-01-02

本研究为ROADSTER多中心前瞻性单臂临床试验,纳入颈动脉内膜切除术高危患者165例,评估经颈动脉血运重建(TCAR)联合ENROUTE动态血流反转系统的1年结局。结果显示1年同侧卒中发生率为0.6%,死亡7例(4.2%)且无神经系统原因死亡,提示TCAR在高危患者中安全且耐久。

要点

  • TCAR联合动态血流反转在高危患者中1年同侧卒中发生率仅0.6%。
  • 1年死亡率为4.2%,无神经系统原因死亡。
  • TCAR可规避主动脉弓操作并减少栓塞,为颈动脉内膜切除术高危患者提供安全血运重建选择。

核心结论

  • TCAR联合动态血流反转在高危患者中1年同侧卒中发生率低,安全耐久。

研究设计与样本

  • ROADSTER多中心前瞻性单臂临床试验,14个中心参与,长期随访纳入165例患者(关键期141例中112例,扩展准入78例中53例)。

主要发现

  • 1年随访同侧卒中发生率为0.6%。
  • 7例患者(4.2%)死亡,无神经系统原因死亡。
  • 平均年龄73.9岁(范围42.1-91.3岁),75岁及以上占43.3%,无症状患者占79.9%。
  • 解剖高危因素包括对侧颈动脉闭塞11.0%、串联狭窄>70% 1.8%、高位颈动脉狭窄25.0%、CEA后再狭窄25.6%、需治疗的双侧狭窄4.3%、颈部放疗史14.6%。
  • 医学高危因素包括双支冠状动脉病变14.0%、左心室功能严重不全射血分数<30% 1.8%;43.3%患者至少有一种解剖高危因素,29.9%有医学高危因素,26.8%两者兼有。

临床怎么用

  • 对于颈动脉内膜切除术高危患者,TCAR联合动态血流反转可作为安全且耐久血运重建选项。

局限性

  • 本研究为单臂临床试验,无对照组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We report the 1-year outcomes of the Safety and Efficacy Study for Reverse Flow Used During Carotid Artery Stenting Procedure (ROADSTER) multicenter trial. This trial introduced a novel transcarotid neuroprotection system (NPS), the ENROUTE transcarotid NPS (Silk Road Medical Inc, Sunnyvale, Calif). Postoperative results demonstrated that the use of the ENROUTE transcarotid NPS is safe and effective. The aim of this study was to evaluate the safety of transcarotid artery revascularization (TCAR) and to present the 1-year outcomes. METHODS: This study is a prospective, single-arm clinical trial. Current enrollment occurs in 14 centers. Primary end points were incidence rates of ipsilateral stroke at 1 year after TCAR. Occurrence of stroke was ascertained by an independent Clinical Events Committee. Patients with anatomic or medical high-risk factors for carotid endarterectomy (CEA) were eligible to be enrolled in the ROADSTER trial. RESULTS: Overall, 165 patients were included in the long-term follow-up (112 of 141 patients from the pivotal phase and 53 of 78 patients from the extended access). Mean age was 73.9 years (range, 42.1-91.3 years). Patients aged 75 years and older were 43.3% of the cohort. The majority of patients were white (92.7%) and male (75.2%). Most patients were asymptomatic (79.9%). Anatomic risk factors were distributed as follows: contralateral carotid artery occlusion (11.0%), tandem stenosis of >70% (1.8%), high cervical carotid artery stenosis (25.0%), restenosis after CEA (25.6%), bilateral stenosis requiring treatment (4.3%), and hostile neck (14.6%). Medical high-risk criteria included two-vessel coronary artery disease (14.0%) and severe left ventricular dysfunction with ejection fraction <30% (1.8%). In general, 43.3% of patients had at least one anatomic high-risk factor, whereas 29.9% of patients had medical high-risk factors. Both subsets of factors were present simultaneously in 26.8% of the cohort. At 1-year follow-up, ipsilateral stroke incidence rate was 0.6%, and seven patients (4.2%) died. None of the deaths were neurologic in origin. CONCLUSIONS: TCAR with dynamic flow reversal had previously shown favorable 30-day perioperative outcomes. This excellent performance seems to extend to 1 year after TCAR as illustrated in this analysis. The promising results from the ROADSTER trial likely stem from the novel cerebral protection provided through the ENROUTE transcarotid NPS in comparison to distal embolic protection devices as well as the transcarotid approach's circumventing diseased aortic arch manipulation and minimizing embolization. TCAR offers a safe and durable revascularization option for patients who are deemed to be at high risk for CEA.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Malas MB, Leal Lorenzo JI, Nejim B, et al. Analysis of the ROADSTER pivotal and extended-access cohorts shows excellent 1-year durability of transcarotid stenting with dynamic flow reversal. J Vasc Surg. 2019. PMID: 30611582. doi:10.1016/j.jvs.2018.08.179

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。